Allergan's most recent trend suggests a bullish bias. One trading opportunity on Allergan is a Bull Put Spread using a strike $115.00 short put and a strike $105.00 long put offers a potential 13.64% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $115.00 by expiration. The full premium credit of $1.20 would be kept by the premium seller. The risk of $8.80 would be incurred if the stock dropped below the $105.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Allergan is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Allergan Announces Quarterly Conference Call
Fri, 10 Jan 2014 00:33:05 GMT
noodls – IRVINE, Calif.–(BUSINESS WIRE)– Allergan, Inc. (NYSE: AGN) invites you to listen to David Pyott, Chairman of the Board and Chief Executive Officer, and Jeff Edwards, Executive Vice President, Finance …
Allergan Announces Quarterly Conference Call
Thu, 09 Jan 2014 22:30:00 GMT
Business Wire – Allergan, Inc. invites you to listen to David Pyott, Chairman of the Board and Chief Executive Officer, and Jeff Edwards, Executive Vice President, Finance and Business Development, Chief Financial Officer, discuss the Company's fourth quarter and full year 2013 results on Wednesday, February 5, 2014.
Why the Risk/Reward Ratio Looks Great for Regeneron Pharmaceuticals Inc.
Thu, 09 Jan 2014 00:52:30 GMT
Motley Fool – There’s risk, but there could be vast rewards for Regeneron Pharmaceuticals Inc.
Valeant's Ambitious 2016 Goal Excites Investors
Wed, 08 Jan 2014 12:00:00 GMT
Morningstar – While guidance for 2014 meets expectations, Valeant sets its sights on becoming a top-five global pharmaceutical company.
Allergan, Inc. and Medytox, Inc. Complete Licensing Agreement
Tue, 07 Jan 2014 15:14:12 GMT
noodls – IRVINE, Calif. & SEOUL, South Korea–(BUSINESS WIRE)– Allergan, Inc., (NYSE: AGN) and Medytox, Inc. today announced that they have closed the license agreement which was previously announced on September …
Related Posts
Also on Market Tamer…
Follow Us on Facebook